AGE, Advanced Glycation End Products:BIO
Catalogue number: AGE612BIO
|Product Type ||Primary Antibodies|
|Units||20 µg |
This antibody is suitable for the detection of different AGE products in tissues, tissue extracts and body fluids. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. These results suggested the potential role of AGE in normal aging and age-enhanced disease processes. Positive: Advanced Glycation Endproducts, AGE-HSA, AGE-BSA, AGE-Hb, AGE-Collagen,AGE-Lys-derivatives (AGE-alpha-Tos-Lys, AGE-alpha-Tos-Lys-o-Me), AGE-monoamino carboxylic acids (AGE-beta-Alanine, AGE-gamma-aminobutyric acid, AGE-epsilon-aminocaproic acid) - negativ: early stages of the Maillard reaction (Schiff's base adducts, Amadori rearrangement products), unmodified protein HSA, BSA, Hb, Collagen, poly-Lys, Lys-derivatives (alpha-Tos-Lys, alpha-Tos-Lys-o-Me), unmodified monoamino carboxylic acids (beta-alanine, gamma-amino butyric acid, epsilon-aminocaproic acid), FFI, Pyrrole aldehyde, Pentosidine..
human lens, arteriosclerotic plaques
Advanced Glycation End Products-BSA
(liquid conc.) ELISA 0.1-0.5 µg/ml; IHC 2 µg/ml
60 min at RT or 18 hr at 2-8°C
Streptavidin:HRPO conjugate (Art. No. ZU054) or alkaline phosphatase conjugate (Art.-Nr. ZU051) in combination with a suitable substrate.
Protein G affinity purified antibody from ascites in stabilized buffer, containing 50% Block Ace? (Casein-containing solution, Dainippon Co.) and 0.1% ProClin? (Rohm & Haas) as a preservative
1. Horiuchi S., Araki N., and Morino Y. (1991) Immunological approach to characterize advanced glycation end products of the Maillard reaction: Evidence for the presence of a common stucture. J. Biol. Chem. 266; 7329-7332.
2. Akari N., Ueno N., Chakrabarti B., Morino Y., and Horiuchi S. (1992) Immunochemical evidence of the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem. 267; 10211-10214.
3. Miyata T., Odo O., Inagi R., Iida Y., Araki N., Yamada N., Horiuchi S., Taniguchi N., Maeda, et al. (1993) ß2-Microglobulin modified with advanced glycation end products is a major component of haemodialysis-associated amyloidosis. J. Clin. Invest. 92; 1243-1252.
4. Kume S., Takeya M., Mori T., Araki N., Suzuki H., Horiuchi S., Kodama T., Miyauchi Y., and Takahashi K. (1995) Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am J. Pathol. 147; 654-667.
5. Kimura T., Takamatsu J., Ikeda K., Kondo A., Miyakawa T., and Horiuchi S. (1996) Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci. Lett. 208; 53-56.
These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.